Keyphrases
Nab-paclitaxel
100%
Cumulative Incidence
100%
Induction Chemotherapy
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Cetuximab
100%
Locally Advanced
100%
Overall Survival
66%
High-risk Human Papillomavirus (HR-HPV)
50%
No Significant Difference
33%
Comparative Analysis
33%
Cisplatin
33%
Annualized Relapse Rate
33%
Treatment Group
16%
Chemoradiation Therapy
16%
Patient Characteristics
16%
Phase II Trial
16%
Tumor Characteristics
16%
5-fluorouracil (5-FU)
16%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
16%
Oropharynx
16%
Disease Survival
16%
Prospective Phase II Study
16%
Hypopharynx
16%
Medicine and Dentistry
Paclitaxel
100%
Induction Chemotherapy
100%
Cumulative Incidence
100%
Head and Neck Squamous Cell Carcinoma
100%
Cetuximab
100%
Disease
75%
Overall Survival
50%
Wart Virus
37%
Cisplatin
25%
Neoplasm
12%
Chemoradiation Therapy
12%
Oropharynx
12%
Phase II Trials
12%
Larynx
12%
Hypopharynx
12%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Chemotherapy
100%
Paclitaxel
100%
Head and Neck Squamous Cell Carcinoma
100%
Cetuximab
100%
Overall Survival
66%
Human Papillomavirus
50%
Cisplatin
33%
Neoplasm
16%
Chemoradiation Therapy
16%
Phase II Trials
16%